Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Bezlotoxumab is approved by both the FDA and EMA for the prevention of Clostridioides difficile infection (CDI) (recurrent) in adults who are receiving antibacterial therapy for CDI and are at high risk for recurrence. It is a monoclonal antibody targeting toxin B produced by C. difficile and is used as an adjunct to standard-of-care antibiotic therapy to reduce the risk of recurrent infection.
A monoclonal antibody …